<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00128856</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM 2002-01</org_study_id>
    <nct_id>NCT00128856</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients</brief_title>
  <official_title>Phase II Pharmacogenomic and Clinical Trial for the Administration of Gemcitabine-doxorubicin-paclitaxel (GAT) as Neoadjuvant Treatment of Patients With Stage III Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <brief_summary>
    <textblock>
      This is a multicenter, open-label, phase II trial to assess the efficacy of the GAT
      neoadjuvant regimen in patients with stage III breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2 treatment cycles of chemotherapy (one cycle = 2 weeks) must be administered to each patient
      before breast surgery.

      The required number of patients has been calculated following Simon's method. 43 patients
      will be enrolled in two phases: first, 29 patients must be enrolled, and at least 2
      pathological complete responses obtained. Patients recruitment will continue until 43
      patients have been enrolled. Assumptions are that there is a 95% probability to obtain a rate
      of pathological complete responses of at least 10%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2003</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (pCR) rate</measure>
    <time_frame>Up to week 15</time_frame>
    <description>pCR is defined as no invasive cells identifiable in breast sections at surgery. Response will be measured by physical exam and breast imaging before surgery and will be evaluated according to the World Health Organization (WHO) criteria. Pathological response after surgery, will be based on the proportion of remaining tumor and post-chemotherapy changes, evaluating separately the response in the breast and in the axilla lymph nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Up to week 12</time_frame>
    <description>Tumor response is defined as the percentage of patients with a complete or partial response out of the patients who had measurable disease at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conservative surgery rate</measure>
    <time_frame>Up to week 15</time_frame>
    <description>To determine the percentage of conservative surgery rate versus other surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Experienced Adverse Events (AE)</measure>
    <time_frame>Through study treatment up to surgery</time_frame>
    <description>According to the Common Terminology Criteria for Adverse Events (CTCAE) version 2.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 5 years since surgery</time_frame>
    <description>Time from the start of treatment to the progression of the disease (if it happens)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue molecular markers and their correlation with response</measure>
    <time_frame>Up to week 15</time_frame>
    <description>Evaluation of changes in the tumor marker profile before and after treatment in tumor samples obtained before and after chemotherapy treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine + Adriamycine + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusion followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Gemcitabine + Adriamycine + Paclitaxel</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycine</intervention_name>
    <arm_group_label>Gemcitabine + Adriamycine + Paclitaxel</arm_group_label>
    <other_name>doxorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Gemcitabine + Adriamycine + Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage III breast cancer disease, with histological confirmation by true-cut or
             open-biopsy.

          -  Ages between 18 and 75 years old. Patients older than 70 must have an adequate quality
             of life to be eligible.

          -  Patients cannot have received previous treatment with chemotherapy, hormone therapy,
             radiotherapy or immune therapy.

          -  Performance status of 0,1, 2 Eastern Cooperative Oncology Group (ECOG).

          -  At least a 6 month life expectancy.

          -  Neutrophils &gt; 1500; platelets &gt; 100000; haemoglobin &gt; 10 mg/dL.

          -  Adequate renal and hepatic functions, with serum creatinine &lt; 1.2 mg/dl and total
             bilirubin &lt; 2 mg/dl.

          -  Adequate contraceptive methods during the study and up to 3 months after.

          -  Adequate cardiac function assessed by physical exam, electrocardiogram and left
             ventricular ejection fraction &gt; 55%.

        Exclusion Criteria:

          -  Inflammatory carcinoma or stage I, II or IV breast cancer disease.

          -  Males.

          -  Active infection.

          -  Other neoplasms except for basal skin carcinoma or cervical in situ carcinoma
             adequately treated. Other previous neoplasms are allowed if diagnosed and treated more
             than 5 years before study registration.

          -  Concomitant serious disease provoking organ failure (heart, renal, hepatic,
             respiratory).

          -  Pre-existing motor or sensorial neuropathy &gt; grade 1.

          -  Inability for treatment compliance.

          -  History of hypersensitivity to compounds such as cremophor, cyclosporine or vitamin K.

          -  History of arrhythmias or congestive heart failure, even when controlled; or active
             cardiac blocking of second or third grade.

          -  History of myocardial infarction in the previous 6 months.

          -  Hypertension not controlled.

          -  Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Miguel Servet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Complejo Hospitalrio de Jaén</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Unviesitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Description Spanish Breast Cancer Research Group (GEICAM) is a Spanish Breast Cancer Research Group</description>
  </link>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 9, 2005</study_first_submitted>
  <study_first_submitted_qc>August 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2005</study_first_posted>
  <last_update_submitted>December 13, 2018</last_update_submitted>
  <last_update_submitted_qc>December 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant chemotherapy.</keyword>
  <keyword>Stage III disease.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

